Giant cell arteritis after COVID-19 vaccination/disease: suggestions for further shots?

Pierangelo Chinello, Francesca Gavaruzzi, Anna Chiara Epifani and Fabrizio Taglietti

Sirs,

We read with great interest the article of Gabrielli and coll. describing a case of giant cell arteritis (GCA) after COVID-19 mRNA vaccine and COVID-19 asymptomatic infection, since we had the opportunity to visit such a patient at our Institution.

Different infectious agents have been suggested to be involved in the pathogenesis of GCA, including Varicella-Zoster Virus, Epstein Barr Virus, Parvovirus B19 and Chlamydia pneumoniae; more recently, the role of SARS-CoV-2 is also under investigation.

Several cases of GCA in SARS-CoV-2 infected patients have been described (Table 1). COVID-19 is known for its immune dysregulation and a strong association between interleukins and rheumatic diseases was found during the COVID-19 pandemic: for example, IL-6 and IL-17 showed association between polymyalgia rheumatica (PMR) and arthritis among COVID-19 patients. Oda et al. reported a case of adult large vessel vasculitis after SARS-CoV-2 infection and hypothesised, after a previous report on endothelial cell infection and endotheliitis in patients with COVID-19, that this infection and endotheliitis could have led to vasculitis. Furthermore, cases of aortitis linked to SARS-CoV-2 infection have been described.

Cases of GCA following SARS-CoV-2 vaccination have also been reported (Table 1). In a pharmacovigilance study using VigiBase, among 2,499,457 spontaneous reports with mRNA COVID-19 vaccines Mettler et al. identified 2125 vasculitis cases (8.5 per 10,000 reports), of which 501 were GCA. However, not only mRNA vaccines have been proposed to be linked to GCA: in a previous report, Mettler et al. observed among 1,295,482 reports concerning COVID-19 vaccines 147 GCA cases, 290 PMR cases and 9 cases of GCA with PMR; cases reported after mRNA vaccine were 61.9% and after viral vector vaccine were 37.4% of the total.

Which could be the mechanisms of post-vaccinal GCA? Liozon et al. reported 10 cases of post-influenza vaccine GCA and reviewed other cases from the literature. Their conclusion was that the onset of GCA or PMR post-influenza vaccine is not exceptional and may be a serious form of autoimmune/inflammatory syndrome induced by adjuvants (ASIA syndrome), especially in people with personal or familial risk of GCA/PMR. ASIA syndrome is thought to be triggered by the adjuvants of the vaccines. However, mRNA SARS-CoV-2 vaccines are considered essentially adjuvant free, but they can themselves stimulate innate immunity with activation of Toll-like receptors (TLRs), notably TLR-7 and TLR-9, which may trigger an autoimmune response.

At the end of their work, the Authors state that they continue to encourage COVID-19 vaccination because the benefits of vaccination far outweigh any theoretical risk of immune dysregulation following administration. We agree with them from a general point of view; however, in this particular patient a synergy between the vaccine immunological stimulation and the subsequent immunological stimulation by the infection could have contributed to the development of GCA. Therefore, we suggest that the need and the advisability of further anti-SARS-CoV-2 vaccine shots should be carefully evaluated for this relatively young patient, taking into account the balance between benefits and risks.

2nd Infectious Diseases Unit, National Institute for Infectious Diseases “L. Spallanzani”, Rome, Italy

Corresponding author:
Pierangelo Chinello, 2nd Infectious Diseases Division, National Institute for Infectious Diseases “L. Spallanzani”, Via Portuense 292, Rome 00149, Italy.
Email: pierangelo.chinello@gmail.com
Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Pierangelo Chinello https://orcid.org/0000-0002-7341-9000

References

1. Gabrielli R, Siani R, Smedile G, et al. Isolated popliteal artery lesion due to giant cell vasculitis post COVID-19 mRNA vaccine and COVID-19 asymptomatic infection. Vascular 2022; 30: 17085381221126234. DOI: 10.1177/17085381221126234.
2. Riera-MartíN, Romani J and Calvet J. SARS-CoV-2 infection triggering a giant cell arteritis. Med Clin (Engl Ed.) 2021; 156: 253–254.
3. Mursi AM, Mirghani HO and Elbeialy AA. A case report of post COVID19 giant cell arteritis and polymyalgia rheumatica with visual loss. Clin Med Insights Case Rep 2022; 15: 1–3.
4. Manzo C, Castagna A and Ruotolo G. Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica? Jt Bone Spine 2021; 88: 105150.
5. Oda R, Inagaki T, Ishikane M, et al. Case of adult large vessel vasculitis after SARS-CoV-2 infection. Ann Rheum Dis 2020; 79: annrheumdis-2020-218440. DOI: 10.1136/annrheumdis-2020-218440.
6. Varga Z, Flammer JA, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–1418.
7. Shergill S, Davies J and Bloomfield J. Florid aortitis following SARS-CoV-2 infection. Eur Heart J 2020; 41: 4286.
8. Silvestri Vand Recchia GE. Aortic Pathology during COVID-19 pandemics. Clinical reports in literature and open questions on the two co-occurring conditions. Ann Vasc Surg 2021; 75: 109–119.
9. Mettler C, Terrier B, Treluyer JM, et al. Risk of systemic vasculitis following mRNA COVID-19 vaccination: a pharmacovigilance study. Rheumatology 2022; 61: keac323. DOI: 10.1093/rheumatology/keac323.
10. Mettler C, Jonville-Bera AP, Grandvuillemin A, et al. Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study. Rheumatology 2022; 61: 865–867.
11. Liozon E, Parreau S, Filloux M, et al. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: a study of 12 patients and a literature review. Autoimmun Rev 2021; 20: 102732.
12. Mejren A, SØrensen CM, Gormsen LC, et al. Large-vessel giant cell arteritis after COVID-19 vaccine. Scand J Rheumatol 2022; 51: 154–155.
13. Ottaviani S, Juge PA, Forien M, et al. Polymyalgia rheumatica following COVID-19 vaccination: a case-series of ten patients. Jt Bone Spine 2022; 89: 105334.
14. Manzo C, Castagna A, Natale M, et al. Answer to Cadiou et al. “SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger?”. Jt Bone Spine 2021; 89: 105284.
15. Anzola AM, Trives L, Martinez-Barrio J, et al. New-onset giant cell arteritis following COVID-19 mRNA (BioNTech/Pfizer) vaccine: a double-edged sword? Clin Rheumatol 2022; 41: 1623–1625.
16. Sauret A, Stievenart J, Smets P, et al. Case of giant cell arteritis after SARS-CoV-2 vaccination: a particular phenotype? J Rheumatol 2022; 49: 120.
17. Greb CS, Aouhab Z, Sisbarro D, et al. A case of giant cell arteritis presenting after COVID-19 vaccination: is it just a coincidence? Cureus 2022; 14: e21608.
18. Gambichler T, Krogias C, Tischoff I, et al. Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination. Br J Dermatol 2022; 186: e83.
19. Cadiou S, Perdriger A, Ardois S, et al. SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? comment on: “Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?” by Manzo et al. joint bone spine 2021. Jt Bone Spine 2022; 89: 105282.
20. Kaulen LD, Doubrovinskaia S, Mooshage C, et al. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. Eur J Neurol 2022; 29: 555–563.
21. Szydelko-Pasko U, Przedziecek-Dolyk J, Krecicka J, et al. Arteritic anterior ischemic optic neuropathy in the course of giant cell Arteritis after COVID-19. Am J Case Rep 2022; 23: e933471.
22. Simao L and Messias A. Giant cell arteritis during COVID-19 pandemic. Arq Bras Oftalmol 2021; 84: 515–516.
23. Jonathan GL, Scott FM and Matthew KD. A case of post-COVID-19-associated paracentral acute middle maculopathy and giant cell arteritis-like vasculitis. J Neuroophthalmol 2021; 41: 351–355.